Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire) - Mar 28, 2023 - "Plus Therapeutics, Inc...announced the first patient in Cohort eight of the ReSPECT-GBM Phase 1/2a dose escalation clinical trial evaluating the Company's lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, in recurrent glioblastoma (GBM) has been successfully treated....In parallel, the Company has treated five patients to date with rhenium (186Re) obisbemeda in the Phase 2 trial in recurrent GBM administering a dose of 22.3 mCi and 8.8 mL in small- to medium-sized tumors....'We remain on track in 2023 to continue to dose escalate to the yet unreached maximal tolerated dose, expand the number of clinical trial sites and present data from the Phase 1/2a and 2 trials in the second half of 2023'."
P1/2 data • P2 data • Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|